Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab Vedotin + Tucatinib in Advanced Solid Tumors
NCT06157892Phase 2Active, not recruiting
- Sponsor
- Pfizer
- Start
- May 2024
- Primary completion
- Jul 2029
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 10
01
Overview
Phase 2, open-label trial of disitamab vedotin in breast cancer, gastric cancer (GC) and gastroesophageal junction adenocarcinoma (7 arms), sponsored by Pfizer. Primary endpoints: Dose Limiting Toxicities at 28 days, Adverse Events at 5 years and 3 more. Started May 2024; status: active, not recruiting.
02
Drugs
disitamab vedotin
03
Conditions
breast cancergastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06157892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06157892.